Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 62.26 | — | 43.50 | 129.86 | 63.28 | 167.97 | 48.45 | 28.22 | 25.38 | 25.19 | 29.00 | 24.33 | 22.25 |
| — | — | -10.2% | +360.2% | +149.3% | +566.8% | +67.1% | +16.0% | +14.1% | -34.9% | -20.0% | +13.8% | -10.2% | |
| P/S Ratio | 7.20 | 6.38 | 5.16 | 11.95 | 11.37 | 21.76 | 8.20 | 7.21 | 5.52 | 4.71 | 6.65 | 6.12 | 5.18 |
| — | -70.7% | -37.1% | +65.8% | +106.1% | +361.6% | +23.4% | +17.7% | +6.5% | -20.3% | +16.0% | -16.7% | -22.0% | |
| P/B Ratio | 9.46 | 6.60 | 6.44 | 15.71 | 13.91 | 20.03 | 8.78 | 8.24 | 6.06 | 5.05 | 7.11 | 6.56 | 5.78 |
| — | -67.1% | -26.7% | +90.7% | +129.5% | +296.3% | +23.6% | +25.7% | +4.8% | +7.1% | +51.0% | +3.8% | -6.8% | |
| P/FCF | 38.65 | — | 27.16 | 45.55 | 50.38 | 681.02 | 25.22 | 18.23 | 22.17 | 29.14 | 152.95 | 14.31 | 14.45 |
| — | — | +7.7% | +149.9% | +127.3% | +2237.3% | -83.5% | +27.3% | +53.4% | +21.0% | +763.8% | -36.2% | -62.0% | |
| EV / EBITDA | 114.94 | — | 204.09 | 229.24 | 80.57 | 876.92 | 56.84 | 27.24 | 24.35 | 22.11 | 26.88 | 23.16 | 18.96 |
| — | — | +259.1% | +741.4% | +230.9% | +3866.9% | +111.5% | +17.6% | +28.4% | -39.2% | +8.8% | +2.9% | -10.2% | |
| EV / EBIT | 119.79 | — | 226.02 | 239.94 | 81.98 | 995.52 | 57.88 | 27.54 | 20.98 | 22.20 | 27.36 | 23.38 | 19.15 |
| — | — | +290.5% | +771.4% | +290.7% | +4385.2% | +111.5% | +17.8% | +9.6% | -40.1% | +7.2% | +1.5% | -11.2% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Corcept Therapeutics Incorporated's operating margin was -30.1% in Q1 2026, down 32.3 pp QoQ and down 32.3 pp YoY. This marks the 4th consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of -2.3% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.3% | 98.3% | 98.7% | 97.8% | 98.2% | 98.5% | 98.4% | 98.4% | 98.5% | 98.3% | 98.6% | 98.7% | 98.7% |
| — | -0.2% | +0.4% | -0.7% | -0.2% | +0.2% | -0.2% | -0.2% | -0.2% | -0.4% | +0.1% | -0.0% | -0.1% | |
| Operating Margin | 5.9% | -30.1% | 2.2% | 4.9% | 13.7% | 2.2% | 13.9% | 25.5% | 21.7% | 20.1% | 23.4% | 25.2% | 25.1% |
| — | -1484.3% | -84.0% | -80.7% | -36.9% | -89.2% | -40.6% | +1.2% | -13.5% | +42.9% | +7.1% | -19.6% | -17.3% | |
| Net Margin | 13.1% | -18.9% | 12.0% | 9.5% | 18.1% | 13.1% | 16.7% | 25.6% | 21.7% | 18.9% | 23.2% | 25.4% | 23.4% |
| — | -244.8% | -28.1% | -63.0% | -16.6% | -30.9% | -27.9% | +0.8% | -7.4% | +25.8% | +43.8% | -25.4% | -11.8% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 15.0% | -4.9% | 3.8% | 3.1% | 5.3% | 3.0% | 4.6% | 7.6% | 6.2% | 5.3% | 6.5% | 7.1% | 5.8% |
| — | -261.0% | -17.7% | -59.0% | -14.1% | -42.7% | -28.8% | +6.4% | +7.2% | +71.0% | +90.2% | -6.0% | -10.2% | |
| ROA | 11.9% | -3.8% | 2.9% | 2.4% | 4.3% | 2.4% | 3.7% | 6.2% | 5.2% | 4.3% | 5.2% | 5.6% | 4.8% |
| — | -255.1% | -21.8% | -61.2% | -17.6% | -44.0% | -27.5% | +11.1% | +7.5% | +64.4% | +73.5% | -16.5% | -15.2% | |
| ROIC | 6.2% | -6.9% | 0.6% | 1.5% | 3.5% | 0.4% | 3.6% | 7.1% | 6.1% | 5.8% | 6.6% | 7.8% | 9.2% |
| — | -1669.8% | -81.9% | -79.6% | -42.7% | -92.3% | -46.1% | -8.7% | -33.8% | +72.1% | +68.1% | +35.8% | +48.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 6.8% YoY to 2.86x, tightening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | +51.0% | -7.6% | -5.3% | +9.3% | +7096.4% | +3324.8% | +2082.8% | +1250.6% | -87.2% | -86.9% | -86.5% | -86.2% | |
| Debt / EBITDA | 0.13 | — | 1.23 | 0.59 | 0.24 | 1.76 | 0.27 | 0.14 | 0.16 | 0.00 | 0.00 | 0.01 | 0.01 |
| — | — | +355.8% | +312.2% | +53.9% | +68586.9% | +5658.1% | +1916.4% | +1491.4% | -93.2% | -90.5% | -86.3% | -85.9% | |
| Current Ratio | 2.92 | 2.86 | 2.92 | 3.14 | 3.06 | 3.07 | 3.35 | 3.70 | 5.57 | 5.18 | 4.39 | 3.54 | 4.65 |
| — | -6.8% | -12.7% | -15.1% | -45.0% | -40.8% | -23.7% | +4.5% | +19.8% | -23.5% | -36.3% | -58.5% | -45.6% | |
| Quick Ratio | 2.85 | 2.77 | 2.85 | 3.07 | 2.98 | 2.96 | 3.26 | 3.64 | 5.48 | 5.10 | 4.31 | 3.48 | 4.57 |
| — | -6.6% | -12.8% | -15.6% | -45.7% | -41.9% | -24.4% | +4.5% | +19.9% | -23.7% | -36.6% | -58.6% | -45.7% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying CORT stock.
Corcept Therapeutics Incorporated's current P/E is 62.3x. The average P/E over the last 3 quarters is 78.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Corcept Therapeutics Incorporated's current operating margin is 5.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Corcept Therapeutics Incorporated's business trajectory between earnings reports.